171 related articles for article (PubMed ID: 11041318)
1. Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder.
Boshuisen ML; den Boer JA
Psychopharmacology (Berl); 2000 Sep; 152(1):74-9. PubMed ID: 11041318
[TBL] [Abstract][Full Text] [Related]
2. Sumatriptan (5-HT1D receptor agonist) does not exacerbate symptoms in obsessive compulsive disorder.
Pian KL; Westenberg HG; van Megen HJ; den Boer JA
Psychopharmacology (Berl); 1998 Dec; 140(3):365-70. PubMed ID: 9877016
[TBL] [Abstract][Full Text] [Related]
3. Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder.
Koran LM; Pallanti S; Quercioli L
Eur Neuropsychopharmacol; 2001 Apr; 11(2):169-72. PubMed ID: 11313163
[TBL] [Abstract][Full Text] [Related]
4. Zolmitriptan-induced growth hormone release in humans: mediation by 5-HT1D receptors?
Whale R; Bhagwagar Z; Cowen PJ
Psychopharmacology (Berl); 1999 Jul; 145(2):223-6. PubMed ID: 10463324
[TBL] [Abstract][Full Text] [Related]
5. Single photon emission computed tomography of the brain with Tc-99m HMPAO during sumatriptan challenge in obsessive-compulsive disorder: investigating the functional role of the serotonin auto-receptor.
Stein DJ; Van Heerden B; Wessels CJ; Van Kradenburg J; Warwick J; Wasserman HJ
Prog Neuropsychopharmacol Biol Psychiatry; 1999 Aug; 23(6):1079-99. PubMed ID: 10621951
[TBL] [Abstract][Full Text] [Related]
6. Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan).
Martin GR; Robertson AD; MacLennan SJ; Prentice DJ; Barrett VJ; Buckingham J; Honey AC; Giles H; Moncada S
Br J Pharmacol; 1997 May; 121(2):157-64. PubMed ID: 9154322
[TBL] [Abstract][Full Text] [Related]
7. Serotonin 5HT1B/1D receptor agonists abolish NMDA receptor-evoked enhancement of nitric oxide synthase activity and cGMP concentration in brain cortex slices.
Stepień A; Chalimoniuk M; Strosznajder J
Cephalalgia; 1999 Dec; 19(10):859-65. PubMed ID: 10668104
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in 5-HT1B/1D receptor antagonists and agonists and their potential therapeutic applications.
Slassi A
Curr Top Med Chem; 2002 Jun; 2(6):559-74. PubMed ID: 12052194
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the vasoconstrictor effects of the selective 5-HT1D-receptor agonist L-775,606 with the mixed 5-HT1B/1D-receptor agonist sumatriptan and 5-HT in human isolated coronary artery.
Longmore J; Maguire JJ; MacLeod A; Street L; Schofield WN; Hill RG
Br J Clin Pharmacol; 2000 Feb; 49(2):126-31. PubMed ID: 10671906
[TBL] [Abstract][Full Text] [Related]
10. The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Kayser V; Aubel B; Hamon M; Bourgoin S
Br J Pharmacol; 2002 Dec; 137(8):1287-97. PubMed ID: 12466238
[TBL] [Abstract][Full Text] [Related]
11. Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice.
de Almeida RM; Nikulina EM; Faccidomo S; Fish EW; Miczek KA
Psychopharmacology (Berl); 2001 Sep; 157(2):131-41. PubMed ID: 11594437
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques.
Nilsson T; Longmore J; Shaw D; Pantev E; Bard JA; Branchek T; Edvinsson L
Eur J Pharmacol; 1999 May; 372(1):49-56. PubMed ID: 10374714
[TBL] [Abstract][Full Text] [Related]
13. Involvement of 5-HT(1B/1D) and 5-HT2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries.
Ellwood AJ; Curtis MJ
Br J Pharmacol; 1997 Nov; 122(5):875-84. PubMed ID: 9384503
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
15. Serotonin-1D hypothesis of obsessive-compulsive disorder: an update.
Zohar J; Kennedy JL; Hollander E; Koran LM
J Clin Psychiatry; 2004; 65 Suppl 14():18-21. PubMed ID: 15554784
[TBL] [Abstract][Full Text] [Related]
16. Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan.
Gross-Isseroff R; Cohen R; Sasson Y; Voet H; Zohar J
Neuropsychobiology; 2004; 50(3):200-5. PubMed ID: 15365215
[TBL] [Abstract][Full Text] [Related]
17. Vascular effects of 5-HT1B/1D-receptor agonists in patients with migraine headaches.
de Hoon JN; Willigers JM; Troost J; Struijker-Boudier HA; Van Bortel LM
Clin Pharmacol Ther; 2000 Oct; 68(4):418-26. PubMed ID: 11061582
[TBL] [Abstract][Full Text] [Related]
18. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Van Haarst AD; Van Gerven JM; Cohen AF; De Smet M; Sterrett A; Birk KL; Fisher AL; De Puy ME; Goldberg MR; Musson DG
Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the human basilar artery contractile response to 5-HT and triptans.
Silva SA; Marques FB; Fontes Ribeiro CA
Fundam Clin Pharmacol; 2007 Jun; 21(3):265-72. PubMed ID: 17521295
[TBL] [Abstract][Full Text] [Related]
20. Cranial vascular effects of zolmitriptan, a centrally active 5-HT1B/1D receptor partial agonist for the acute treatment of migraine.
MacLennan SJ; Cambridge D; Whiting MV; Marston C; Martin GR
Eur J Pharmacol; 1998 Nov; 361(2-3):191-7. PubMed ID: 9865508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
